|
2025-01-03 |
2024-12-31 |
S
Sale
|
Vieser Jaime
Non-Executive Director
|
818
-3.1%
2.00
USD 1,636
|
818
-3.1%
|
2.00
|
USD 1,636
|
|
|
2025-01-03 |
2024-12-31 |
S
Sale
|
Vieser Jaime
Non-Executive Director
|
2,182
-7.6%
2.01
USD 4,386
|
2,182
-7.6%
|
2.01
|
USD 4,386
|
|
|
2023-09-05 |
2023-09-01 |
PS
Planned sale
|
Boyle Kevin S. Sr.
Chief Executive Officer
Executive Director
|
68,014
-7.9%
0.14
USD 9,542
|
68,014
-7.9%
|
0.14
|
USD 9,542
|
|
|
2022-12-01 |
2022-11-29 |
B
Purchase
|
Postma Robert W
Non-Executive Director
|
750,000
+17.6%
0.65
USD 487,500
|
750,000
+17.6%
|
0.65
|
USD 487,500
|
|
|
2022-12-01 |
2022-11-29 |
B
Purchase
|
Vieser Jaime
Non-Executive Director
|
1,250,000
+inf%
0.65
USD 812,500
|
1,250,000
+inf%
|
0.65
|
USD 812,500
|
|
|
2021-11-17 |
2021-11-17 |
B
Purchase
|
Boyle Kevin S. Sr.
Chief Executive Officer
Executive Director
|
9,116
+1.0%
1.40
USD 12,762
|
9,116
+1.0%
|
1.40
|
USD 12,762
|
|
|
2021-11-17 |
2021-11-16 |
B
Purchase
|
Boyle Kevin S. Sr.
Chief Executive Officer
Executive Director
|
884
+0.1%
1.40
USD 1,238
|
884
+0.1%
|
1.40
|
USD 1,238
|
|
|
2021-10-04 |
2021-09-29 |
B
Purchase
|
Vieser Jaime
Non-Executive Director
|
100,000
+16.5%
1.91
USD 191,000
|
100,000
+16.5%
|
1.91
|
USD 191,000
|
|
|
2021-09-03 |
2021-09-02 |
B
Purchase
|
Postma Robert W
Non-Executive Director
|
54,492
+1.3%
1.73
USD 94,271
|
54,492
+1.3%
|
1.73
|
USD 94,271
|
|
|
2021-09-03 |
2021-09-02 |
B
Purchase
|
Postma Robert W
Non-Executive Director
|
20,508
+1.7%
1.73
USD 35,479
|
20,508
+1.7%
|
1.73
|
USD 35,479
|
|
|
2021-01-12 |
2021-01-08 |
PS
Planned sale
|
Buck Jill
EVP, GM Gene Therapy
Officer
|
27,894
-12.3%
3.12
USD 87,029
|
27,894
-12.3%
|
3.12
|
USD 87,029
|
|
|
2021-01-12 |
2021-01-08 |
PS
Planned sale
|
Lafond Kevin G
SVP, Treasurer & CAO
Officer
|
18,020
-22.0%
3.09
USD 55,682
|
18,020
-22.0%
|
3.09
|
USD 55,682
|
|
|
2021-01-12 |
2021-01-08 |
PS
Planned sale
|
Hadfield Robert
General Counsel and Secretary
Officer
|
26,500
-16.6%
3.12
USD 82,680
|
26,500
-16.6%
|
3.12
|
USD 82,680
|
|
|
2021-01-06 |
2021-01-04 |
PS
Planned sale
|
De Groot Eleanor
EVP, GM Cell Therapy
Officer
|
21,620
-9.5%
2.72
USD 58,806
|
21,620
-9.5%
|
2.72
|
USD 58,806
|
|
|
2021-01-06 |
2021-01-04 |
PS
Planned sale
|
Cooper Laurence James Neil
President and CEO
Executive Director
|
105,693
-5.5%
2.71
USD 286,428
|
105,693
-5.5%
|
2.71
|
USD 286,428
|
|
|
2020-01-03 |
2020-01-02 |
PS
Planned sale
|
MAUNEY DAVID M MD
President
Officer
|
22,394
-10.3%
4.55
USD 101,893
|
22,394
-10.3%
|
4.55
|
USD 101,893
|
|
|
2020-01-03 |
2020-01-02 |
PS
Planned sale
|
Buck Jill
EVP, GM Gene Therapy
Officer
|
27,923
-13.8%
4.55
USD 127,050
|
27,923
-13.8%
|
4.55
|
USD 127,050
|
|
|
2020-01-03 |
2020-01-02 |
PS
Planned sale
|
De Groot Eleanor
EVP, GM Cell Therapy
Officer
|
24,890
-12.5%
4.55
USD 113,250
|
24,890
-12.5%
|
4.55
|
USD 113,250
|
|
|
2020-01-03 |
2020-01-02 |
PS
Planned sale
|
Hadfield Robert
General Counsel and Secretary
Officer
|
16,853
-14.3%
4.55
USD 76,681
|
16,853
-14.3%
|
4.55
|
USD 76,681
|
|
|
2020-01-03 |
2020-01-02 |
PS
Planned sale
|
Lafond Kevin G
SVP, Treasurer & CAO
Officer
|
21,570
-25.2%
4.55
USD 98,144
|
21,570
-25.2%
|
4.55
|
USD 98,144
|
|
